Respiratory & Anti-Allergic Tablet Franchise in Ahmedabad

Bilastuff AB 20 Tablet Supplier in Mumbai

Bilastine Acebrophylline Tablet Distributor in Delhi

Bronchodilator & Anti-Allergic Tablet Manufacturer in Bangalore

Asthma & Allergy Tablet Stockist in Hyderabad
Respiratory Therapy Tablet Exporter in Chandigarh

Home/Products /bilastine-20mg-acebrophylline-200mg-tablet

Bilastuff AB 20 Tablet

Composition : Bilastine (10mg) + Acebrophylline (200mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Bilastuff AB 20 Tablet combines Bilastine 20mg, a potent non-sedating H1-antihistamine, with Acebrophylline 200mg, a bronchodilator and mucolytic agent. This combination is designed to provide comprehensive relief in allergic and obstructive airway conditions by reducing histamine-induced symptoms and improving airway patency.

Clinically, it is indicated for bronchial asthma, chronic bronchitis, allergic rhinitis, and other respiratory hypersensitivity or obstructive conditions. Bilastine helps alleviate sneezing, nasal congestion, and itching, while Acebrophylline promotes bronchodilation, mucus clearance, and airway relaxation, enhancing overall respiratory function.

The tablet formulation ensures accurate dosing, consistent therapeutic effect, and rapid symptomatic relief, making it ideal for pulmonology clinics, ENT and allergy centers, hospitals, and specialty pharmacies. It supports improved airflow, symptom control, and enhanced patient comfort under medical supervision.

Bilastuff AB 20 Tablet helps in reducing airway inflammation, relieving nasal and bronchial allergy symptoms, improving lung function, and providing effective respiratory support. Its combination of antihistamine and bronchodilator effects makes it a trusted therapy for patients with asthma and allergic respiratory disorders.


Read More

About the Product

Bilastuff AB 20 Tablet combines Bilastine 20mg, a potent non-sedating H1-antihistamine, with Acebrophylline 200mg, a bronchodilator and mucolytic agent. This combination is designed to provide comprehensive relief in allergic and obstructive airway conditions by reducing histamine-induced symptoms and improving airway patency.

Clinically, it is indicated for bronchial asthma, chronic bronchitis, allergic rhinitis, and other respiratory hypersensitivity or obstructive conditions. Bilastine helps alleviate sneezing, nasal congestion, and itching, while Acebrophylline promotes bronchodilation, mucus clearance, and airway relaxation, enhancing overall respiratory function.

The tablet formulation ensures accurate dosing, consistent therapeutic effect, and rapid symptomatic relief, making it ideal for pulmonology clinics, ENT and allergy centers, hospitals, and specialty pharmacies. It supports improved airflow, symptom control, and enhanced patient comfort under medical supervision.

Bilastuff AB 20 Tablet helps in reducing airway inflammation, relieving nasal and bronchial allergy symptoms, improving lung function, and providing effective respiratory support. Its combination of antihistamine and bronchodilator effects makes it a trusted therapy for patients with asthma and allergic respiratory disorders.


Common side effects may include mild headache, dizziness, dry mouth, or gastrointestinal discomfort. Rarely, hypersensitivity reactions, palpitations, or sleep disturbances may occur.

Bilastuff AB 20 Tablet is indicated for the management of allergic rhinitis, chronic bronchitis, asthma, and other respiratory conditions characterized by bronchospasm, mucus retention, and allergic responses, as prescribed by a healthcare professional.

Use under medical supervision. Caution is advised in patients with renal or hepatic impairment. Avoid abrupt discontinuation of therapy. Not recommended during pregnancy or lactation unless specifically prescribed by a physician.

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation